NASDAQ:STIM Neuronetics (STIM) Stock Price, News & Analysis → Jeff Bezos & 48 Members of Congress Are Buying ONE Sector… (From InvestorPlace) (Ad) Free STIM Stock Alerts $2.02 -0.04 (-1.94%) (As of 06/14/2024 08:52 PM ET) Add Compare Share Share Today's Range$1.94▼$2.0850-Day Range$1.90▼$4.4352-Week Range$1.03▼$5.07Volume99,200 shsAverage Volume177,830 shsMarket Capitalization$60.60 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Neuronetics alerts: Email Address Neuronetics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside296.0% Upside$8.00 Price TargetShort InterestHealthy0.32% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.47Based on 5 Articles This WeekInsider TradingAcquiring Shares$102,500 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.91) to ($0.61) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.19 out of 5 starsMedical Sector556th out of 913 stocksSurgical & Medical Instruments Industry65th out of 99 stocks 3.5 Analyst's Opinion Consensus RatingNeuronetics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNeuronetics has only been the subject of 1 research reports in the past 90 days.Read more about Neuronetics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.32% of the outstanding shares of Neuronetics have been sold short.Short Interest Ratio / Days to CoverNeuronetics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neuronetics has recently increased by 436.67%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeuronetics does not currently pay a dividend.Dividend GrowthNeuronetics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for STIM. Previous Next 1.9 News and Social Media Coverage News SentimentNeuronetics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Neuronetics this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 2 people have added Neuronetics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neuronetics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $102,500.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 9.80% of the stock of Neuronetics is held by insiders.Percentage Held by Institutions53.59% of the stock of Neuronetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Neuronetics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Neuronetics are expected to grow in the coming year, from ($0.91) to ($0.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neuronetics is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neuronetics is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuronetics has a P/B Ratio of 1.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Neuronetics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Freeport SocietyBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend into chaos.Click here now to see my urgent election warning. About Neuronetics Stock (NASDAQ:STIM)Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.Read More STIM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart STIM Stock News HeadlinesJune 7, 2024 | insidertrades.comRobert Cascella Purchases 50,000 Shares of Neuronetics, Inc. (NASDAQ:STIM) StockJune 13, 2024 | globenewswire.comNeuroStar Showcases Cutting-Edge Research at Clinical TMS Society Annual MeetingJune 12, 2024 | americanbankingnews.comReviewing Vivos Therapeutics (NASDAQ:VVOS) & Neuronetics (NASDAQ:STIM)June 9, 2024 | americanbankingnews.comInsider Buying: Neuronetics, Inc. (NASDAQ:STIM) Director Purchases $102,500.00 in StockMay 24, 2024 | msn.comNeuronetics to Present at William Blair Growth ConferenceMay 23, 2024 | globenewswire.comNeuronetics to Present at the William Blair 44th Annual Growth Stock ConferenceMay 15, 2024 | msn.comWilliam Blair Upgrades Neuronetics (STIM)May 15, 2024 | globenewswire.comHumana Is First Commercial Payer to Address TMS Therapy Coverage for AdolescentsMay 10, 2024 | msn.comNeuronetics Boasts 12% Revenue Increase, Expands Depression Treatment SectorMay 9, 2024 | finance.yahoo.comNeuronetics, Inc. (NASDAQ:STIM) First-Quarter Results: Here's What Analysts Are Forecasting For This YearMay 9, 2024 | seekingalpha.comNeuronetics: Reality Set InMay 8, 2024 | markets.businessinsider.comStrong Buy Rating for Neuronetics Backed by Solid Financials and Growth ProspectsMay 8, 2024 | finance.yahoo.comNeuronetics, Inc. (NASDAQ:STIM) Q1 2024 Earnings Call TranscriptMay 8, 2024 | markets.businessinsider.comBuy Rating on Neuronetics: Solid Fundamentals and Growth Despite ChallengesMay 8, 2024 | finance.yahoo.comNeuronetics Inc (STIM) (Q1 2024) Earnings Call Transcript Highlights: Strategic Growth Amidst ...May 8, 2024 | wsj.comNeuronetics Inc.May 7, 2024 | msn.comNeuronetics GAAP EPS of -$0.27 beats by $0.04, revenue of $17.42M beats by $0.3MMay 7, 2024 | msn.comSTIM Stock Earnings: Neuronetics Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | finance.yahoo.comNeuronetics Inc (STIM) Reports Q1 2024 Earnings: Revenue Surpasses Estimates, Narrowing LossesMay 7, 2024 | globenewswire.comNeuronetics Reports Record First Quarter 2024 Financial and Operating ResultsMay 6, 2024 | msn.comNeuronetics Q1 2024 Earnings PreviewMay 4, 2024 | finance.yahoo.comNeuronetics, Inc. (STIM)May 4, 2024 | msn.comNeuronetics Awards Stock Options to New Employees as InducementMay 3, 2024 | globenewswire.comNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 1, 2024 | globenewswire.comNeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness MonthSee More Headlines Receive STIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neuronetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today6/16/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:STIM CUSIPN/A CIK1227636 Webwww.neurostar.com Phone(610) 640-4202Fax610-640-4206Employees203Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+296.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,190,000.00 Net Margins-37.61% Pretax Margin-37.61% Return on Equity-75.84% Return on Assets-26.67% Debt Debt-to-Equity Ratio2.15 Current Ratio5.65 Quick Ratio5.18 Sales & Book Value Annual Sales$71.35 million Price / Sales0.85 Cash FlowN/A Price / Cash FlowN/A Book Value$1.18 per share Price / Book1.71Miscellaneous Outstanding Shares30,000,000Free Float27,058,000Market Cap$60.60 million OptionableOptionable Beta2.32 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Keith J. Sullivan (Age 66)President, CEO & Director Comp: $1.39MMr. Stephen J. Furlong M.S. (Age 60)Executive VP, CFO & Treasurer Comp: $771.38kMr. W. Andrew Macan (Age 51)Executive VP, GC, Chief Compliance Officer & Corporate Secretary Comp: $629.7kMr. Rusty PageSenior VP of Operations & QualityMs. Lisa Metzner-RosasSenior VP & Chief Marketing OfficerMs. Sara GrubbsSenior VP & Chief Revenue OfficerMr. Rick GrubbsSenior Vice President of National AccountsMr. Cory S. AndersonSenior Vice President of R&D and ClinicalMore ExecutivesKey CompetitorsPolyPidNASDAQ:PYPDLyra TherapeuticsNASDAQ:LYRAPAVmedNASDAQ:PAVMUtah Medical ProductsNASDAQ:UTMDAVITA MedicalNASDAQ:RCELView All CompetitorsInsiders & InstitutionsRobert CascellaBought 50,000 shares on 6/6/2024Total: $102,500.00 ($2.05/share)Silvercrest Asset Management Group LLCBought 51,881 shares on 5/16/2024Ownership: 3.928%Kent Lake Capital LLCSold 94,890 shares on 5/16/2024Ownership: 3.404%FourWorld Capital Management LLCBought 35,921 shares on 5/16/2024Ownership: 0.120%Vanguard Group Inc.Sold 53,229 shares on 5/10/2024Ownership: 4.337%View All Insider TransactionsView All Institutional Transactions STIM Stock Analysis - Frequently Asked Questions Should I buy or sell Neuronetics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" STIM shares. View STIM analyst ratings or view top-rated stocks. What is Neuronetics' stock price target for 2024? 2 analysts have issued 12-month price targets for Neuronetics' shares. Their STIM share price targets range from $8.00 to $8.00. On average, they anticipate the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 296.0% from the stock's current price. View analysts price targets for STIM or view top-rated stocks among Wall Street analysts. How have STIM shares performed in 2024? Neuronetics' stock was trading at $2.90 at the beginning of the year. Since then, STIM shares have decreased by 30.3% and is now trading at $2.02. View the best growth stocks for 2024 here. Are investors shorting Neuronetics? Neuronetics saw a increase in short interest in May. As of May 31st, there was short interest totaling 96,600 shares, an increase of 436.7% from the May 15th total of 18,000 shares. Based on an average daily trading volume, of 164,400 shares, the short-interest ratio is currently 0.6 days. View Neuronetics' Short Interest. When is Neuronetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our STIM earnings forecast. How were Neuronetics' earnings last quarter? Neuronetics, Inc. (NASDAQ:STIM) issued its earnings results on Tuesday, May, 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.06. The business had revenue of $17.42 million for the quarter, compared to analysts' expectations of $17.10 million. Neuronetics had a negative net margin of 37.61% and a negative trailing twelve-month return on equity of 75.84%. What guidance has Neuronetics issued on next quarter's earnings? Neuronetics updated its second quarter 2024 earnings guidance on Wednesday, May, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $18.0 million-$19.0 million, compared to the consensus revenue estimate of $19.5 million. What other stocks do shareholders of Neuronetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Novavax (NVAX), Gilead Sciences (GILD), iBio (IBIO), Onconova Therapeutics (ONTX), Pfizer (PFE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT) and Acasti Pharma (ACST). When did Neuronetics IPO? Neuronetics (STIM) raised $75 million in an initial public offering on Thursday, June 28th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Piper Jaffray and William Blair acted as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers. Who are Neuronetics' major shareholders? Neuronetics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.34%), Silvercrest Asset Management Group LLC (3.93%), Kent Lake Capital LLC (3.40%), Acadian Asset Management LLC (0.88%), Assenagon Asset Management S.A. (0.28%) and David J Yvars Group (0.23%). Insiders that own company stock include Bruce Joseph Shook, Cannell Capital Llc, Keith J Sullivan, Robert Cascella, Stephen Furlong and William Andrew Macan. View institutional ownership trends. How do I buy shares of Neuronetics? Shares of STIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:STIM) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored(Free Workshop) Advanced “bug-out bag” hacks!“Do you have a ‘bug-out bag’ (survival kit) ready to grab-and-go when a disaster or other crisis strikes?” ...Warrior Life | SponsoredSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the ...Crypto 101 Media | SponsoredElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine...InvestorPlace | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuronetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuronetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.